Near-term strategies for biotech drug developers facing shifting healthcare dynamics

A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.

Read the full article

Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”

Watch the full video

The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.

Return to Insights Center